IV Busulfan With Allo-BMT: Study for Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome
Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if giving busulfan in a dose based on
blood levels, along with a fixed (unchanging) dose of fludarabine, is more effective and
causes fewer side effects for AML or myelodysplastic syndrome patients than the standard
method of giving a fixed busulfan dose based on body size, along with a fixed dose of
fludarabine. The safety of dosing based on blood levels will also be studied.